The neuroleptic drug pimozide inhibits stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma

Oncotarget

Volumn 8, Issue 11, 2017, Pages 17593-17609

  Chen, Jia Jie ^a,b   Cai, Nan ^a,b   Chen, Guan Zhong ^a   Jia, Chang Chang ^a,b   Qiu, Dong Bo ^a,b   Du, Cong ^a,b   Liu, Wei ^a   Yang, Yang ^a   Long, Zi Jie ^b   Zhang, Qi ^a,b  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Hepatic cancer stem like cells; Pimozide; Self renewal; STAT3 inhibitor; STAT3 signaling

Indexed keywords

INTERLEUKIN 6; PIMOZIDE; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; NEUROLEPTIC AGENT; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BCL XL GENE; CANCER CELL; CARCINOGENICITY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL MIGRATION; CELL PROLIFERATION; CELL SELF-RENEWAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MCL 1 GENE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE C MYC; PHENOTYPE; PROTEIN PHOSPHORYLATION; STEM CELL; TUMOR VOLUME; ANIMAL; BIOSYNTHESIS; CANCER STEM CELL; DRUG EFFECTS; DRUG SCREENING; LIVER TUMOR; MALE; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIPSYCHOTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; PIMOZIDE; REAL-TIME POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85015161744     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4307     Document Type: Article

References (51)

1. Boguski MS, Mandl KD and Sukhatme VP. Drug discovery. Repurposing with a difference. Science. 2009; 324(5933): 1394-1395.
2. Carley DW. Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part I. IDrugs. 2005; 8: 306-309.
3. Carley DW. Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part II. IDrugs. 2005; 8: 310-313.
4. Blatt J and Corey SJ. Drug repurposing in pediatrics and pediatric hematology oncology. Drug Discov Today. 2013; 18: 4-10.
5. Kasznicki J, Sliwinska A and Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med. 2014; 2: 57.
6. Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B and Menendez JA. Metformin: Multi-faceted protection against cancer. Oncotarget. 2011; 2: 896-917.
7. Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, Luk M, Kast RE, Kong E, Toyota E, Yip S, Toyota B and Dunn SE. Disulfiram, a drug widely used to control alcoholism, suppresses self-renewal of glioblastoma and overrides resistance to temozolomide. Oncotarget. 2012; 3: 1112-1123.
8. Fishman MC and Porter JA. Pharmaceuticals: a new grammar for drug discovery. Nature. 2005; 437: 491-493.
9. Saponara M, Pantaleo MA, Nannini M and Biasco G. Treatments for gastrointestinal stromal tumors that are resistant to standard therapies. Future Oncol. 2014; 10: 2045-2059.
10. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP and Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013; 109: 1725-1734.
11. Ana Maria C and Catherine F. Current Management of Hepatocellular Carcinoma. Gastroenterol Hepatol (NY). 2014; 10: 153-161.
12. Hoshida Y, Fuchs BC and Tanabe KK. Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Current cancer drug targets. 2012; 12: 1129-1159.
13. Altekruse SF, McGlynn KA and Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009; 27: 1485-1491.
14. Lopa M, Tanuj B, Joseph M, Stephen B, Arun T, Aiwu RH, Kirti S, Lynt J and E. P. Reddy. Liver Stem Cells and Hepatocellular Carcinoma. Hepatology. Hepatology. 2009; 49: 318-329.
15. Ji JF and Wang XW. Clinical Implications of Cancer Stem Cell Biology in Hepatocellular Carcinoma. Semin Oncol. 2012; 39: 461-472.
16. Seung KY. The Biology of Cancer Stem Cells and Its Clinical Implication in Hepatocellular Carcinoma. Gut Liver. 2012; 6: 29-40.
17. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene. 2006; 25: 3818-3822.
18. Caecilia HS, Natalia R, Lory SC and Claudio T. Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World J Hepatol. 2010; 2: 114-126.
19. Melchiorre C, James AM, Antonella C, Nadia L, Antonina A and Giuseppe M. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget. 2012; 3: 236-260.
20. Egolf A and Coffey BJ. Current pharmacotherapeutic approaches for the treatment of Tourette syndrome. Drugs Today (Barc). 2014; 50: 159-179.
21. Taub RN and Baker MA. Treatment of metastatic malignant melanoma with pimozide. Lancet. 1979; 1: 605.
22. Strobl JS, Kirkwood KL, Lantz TK, Lewine MA, Peterson VA and Worley JF. Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine. Cancer Res. 1990; 50: 5399-5405.
23. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, Ebert BL, Griffin JD and Frank DA. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011; 117: 3421-3429.
24. Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, Liu S, Kharbanda S, Christie AL, Nicolais M, Griffin JD, Stone RM, Kung AL and Frank DA. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes Cancer. 2012; 3: 503-511.
25. Strobl JS, Melkoumian Z, Peterson VA and Hylton H. The cell death response to gamma-radiation in MCF-7 cells is enhanced by a neuroleptic drug, pimozide. Breast Cancer Res Treat. 1998; 51: 83-95.
26. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PloS one. 2008; 3: e3077.
27. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H and Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006; 44: 240-251.
28. Wu Q, Wang R, Yang Q, Hou X, Chen SL, Hou YY, Chen CJ, Yang Y, Miele L, Sarkar FH, Chen YQ and Wang ZW. Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway. Oncotarget. 2013; 4: 1999-2009.
29. Hu C, Li H, Li JJ, Zhu Z, Yin SY, HaoXF, Yao M, Zheng SS and GuJR. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis. 2008; 29: 2289-2297.
30. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract. 2008; 62: 1212-1218.
31. Siddiquee KAZ and Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell research. 2008; 18: 254-267.
32. Yao Z and Mishra L. Cancer stem cells and hepatocellular carcinoma. Cancer biology & therapy 2009; 8: 1691-1698.
33. Hodge DR, Hurt EM and Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005; 41: 2502-2512.
34. Ashburn TT and Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3: 673-683.
35. Villanueva A and Llovet JM. Targeted Therapies for Hepatocellular Carcinoma. Gastroenterology. 2011; 140: 1410-1426.
36. Lorenzo CR and Koo J. Pimozide in dermatologic practice: a comprehensive review. Am J Clin Dermatol. 2004; 5: 339-349.
37. Ma S, Lee TK, Zheng BJ, Chan KW and Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008; 27: 1749-1758.
38. Yin, S., Li, J., Hu, C., Chen, X., Yao, M., Yan, M., Jiang, G., Ge, C., Xie, H., Wan, D., Yang, S., Zheng, S. and Gu, J. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer. 2007; 120: 1444-1450.
39. Yu H, Kortylewski M and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007; 7: 41-51.
40. Wang X, Crowe PJ, Goldstein D and Yang JL. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int J Oncol. 2012; 41: 1181-1191.
41. Kusaba M, Nakao K, Goto T, Nishimura D, Kawashimo H, Shibata H, Motoyoshi Y, Taura N, Ichikawa T, Hamasaki K and Eguchi K. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J Hepatol 2007; 47: 546-555.
42. Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ren WH, Ge YS, Yu JH, Liu WB and Wang W. Activation of STAT3 signal pathway correlates with twist and E-cadherin expression in hepatocellular carcinoma and their clinical significance. J Surg Res. 2012; 174: 120-129.
43. Wu WY, Li J, Wu ZS, Zhang CL, Meng XL and Lobie PE. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in hepatocellular carcinoma. Exp Ther Med. 2011; 2: 647-653.
44. Fuke H, Shiraki K, Sugimoto K, Tanaka J, Beppu T, Yoneda K, Yamamoto N, Ito K, Masuya M and Takei Y. Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2007; 363: 738-744.
45. Chen KF, Tai WT, Liu TH, Huang HP, Lin YC, Shiau CW, Li PK, Chen PJ and Cheng AL. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin Cancer Res. 2010; 16: 5189-5199.
46. Deng P1, Wang C, Chen L, Wang C, Du Y, Yan X, Chen M, Yang G and He G. Sesamin induces cell cycle arrest and apoptosis through the inhibition of signal transducer and activator of transcription 3 signalling in human hepatocellular carcinoma cell line HepG2. Biol Pharm Bull. 2013; 36: 1540-1548.
47. Song X, Wang J, Zheng T, Song R, Liang Y, Bhatta N, Yin D, Pan S, Liu J, Jiang H and Liu L. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway. Mol Cancer. 2013; 12: 114.
48. Krishnamurthy S, Warner KA, Dong Z, Imai A, Nör C, Ward BB, Helman JI, Taichman RS, Bellile EL, McCauley LK, Polverini PJ, Prince ME, Wicha MS and Nör JE. Endothelial interleukin-6 defines the tumorigenic potential of primary human cancer stem cells. Stem Cells. 2014; 32: 2845-2857.
49. Soll C, Riener MO, Oberkofler CE, Hellerbrand C, Wild PJ, DeOliveira ML and Clavien PA. Expression of serotonin receptors in human hepatocellular cancer. Clin Cancer Res. 2012; 18: 5902-5910.
50. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B and Hassanali M. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008; 36: D901-D906.
51. Rondanin R, Simoni D, Romagnoli R, Baruchello R, Marchetti P, Costantini C, Fochi S, Padroni G, Grimaudo S, Pipitone RM, Meli M and Tolomeo M. Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives. Bioorg Med Chem Lett. 2014; 24: 4568-4574.